Latest AstraZeneca News

Targeting leukemia’s survival route: a novel approach to overcoming leukemia recurrence
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
Masks work, our comprehensive review has found
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
AstraZeneca’s COVID vaccine withdrawn – right to the end it was the victim of misinformation
AstraZeneca to partner with KI and Karolinska University Hospital in precision medicine
Life prolonging breast cancer drug recommended for PBS subsidy, but it is not time to celebrate
We looked at genetic clues to depression in more than 14,000 people. What we found may surprise you
Life prolonging breast cancer drug recommended for PBS subsidy, but it is not time to celebrate
Scientists unveil cutting-edge ruthenium catalyst for new reaction discovery and optimisation
Oxidative stress in heart failure varies between males and females
LBT Innovations announces that its APAS PharmaQC product is commercially ready
Study Shows How Oestrogen Protects Against Fatty Liver
Two datopotamab deruxtecan applications validated in the EU for patients with advanced nonsquamous non-small cell lung cancer or HR-positive, HER2-negative breast cancer
New Monitoring Tool Is Making Vaccine Rollouts Safer
Big Data Detects Covid Vaccine Safety Signals
Acquisition Of Gracell Completed
LBT Innovations confirms deliver of APAS PharmaQC to Thermo Fisher
Acquisition of Icosavax Completed
Tagrisso with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer
Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial
Tagrisso with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer
Full Year and Q4 2023 results
Positive high-level results from Japan Phase III trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) showed consistency with global ATTRibute-CM…
Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours
Imfinzi plus transarterial chemoembolisation (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer…
Method improves detection of potential therapeutic tumor targets in human biopsies
Combo treatment improves lung cancer outcomes
ISU researcher wins innovation challenge to seek RNA drug targets
Beyfortus approved in China for the prevention of RSV disease in infants
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases
Wainua (eplontersen) granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
AstraZeneca to acquire Icosavax, including potential first-in-class RSV and hMPV combination vaccine with positive Phase II data
AstraZeneca advances scientific leadership in haematology at ASH 2023
AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes
Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer
Imfinzi plus chemotherapy approved in China as first immunotherapy regimen for patients with locally advanced or metastatic biliary tract cancer
Update on PACIFIC-2 Phase III trial of Imfinzi concurrently administered with platinum-based chemoradiotherapy in unresectable, Stage III non-small cell lung cancer
Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial
9M and Q3 2023 results
Zibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial
ZORA real-world evidence demonstrates that Lokelma substantially increases cardiorenal patients’ chances of maintaining lifesaving RAASi therapy
AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions
‘Immune confusion’ leads to severe dengue in children: study
US Food and Drug Administration accepts for review AstraZeneca’s Supplemental Biologics License Application for self-administration of FluMist Quadrivalent
Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial
Enhertu demonstrated clinically meaningful survival across multiple HER2-expressing advanced solid tumours in DESTINY-PanTumor02 Phase II trial